多泽润、DacoMitinib、Dacoplice、 PF299804
多泽润、DacoMitinib、Dacoplice、 PF299804

Dacomitinib 15mg/45mg

Another Name
多泽润、DacoMitinib、Dacoplice、 PF299804
Indications
The first-line treatment for metastatic non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21L858R substitution mutation.
Reg No
06 L 1115/24,06 L 1116/24
Inspection No
1061-24/1063-24
dosage form:Pills
Specs:15mg/45mg * 30 Pills
Indate:24 months
Date：2024-9-1 Views：1001
Drug Info

COMPOSITION:

Each film-coated tablet contains Dacomitinib……………………………. 15mg/45mg.

INDICATION:

LuciDac is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations.

DOSAGE AND USE:

Recommended Dosage: 15mg/45mg orally once daily with or without food.

STORAGE:

In a dry place and store at 20°C to 25°C.

MANUFACTURED AND MARKETED BY:

LUCIUS PHARMACEUTICALS(LAO) CO., LTD

No.26, Thongmang village, Xaythany district, Vientiane Capital, Laos

WARNING:

Keep medicine out of reach of Children. Do not administer LuciDac during Pregnancy and Lactation.

Original article, if reprinted, please indicate the link to this article: https://lucius-pharmaceuticals.com/drug/dacomitinib/

Related News